Cargando…
Safety and immunogenicity of a hexavalent DTwP-IPV-HB-PRP∼T vaccine versus separate DTwP-HB-PRP∼T and IPV vaccines in healthy infants in India
BACKGROUND: Multivalent vaccines containing whole-cell pertussis (wP) antigens combined with established diphtheria (D), tetanus (T), hepatitis B (HB), Haemophilus influenzae type b (Hib), and inactivated poliomyelitis (IPV) antigens allow the provision of a high-quality, affordable DTwP-IPV-HB-PRP∼...
Autores principales: | Mangarule, S., Palkar, S., Mitra, M., Ravi, M.D., Dubey, A.P., Moureau, A., Jayanth, M.V., Patel, D.M., Ravinuthala, S., Jagga, S.R., Patnaik, B.N., Jordanov, E., Noriega, F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019696/ https://www.ncbi.nlm.nih.gov/pubmed/35462885 http://dx.doi.org/10.1016/j.jvacx.2021.100137 |
Ejemplares similares
-
Antibody persistence following administration of a hexavalent DTwP-IPV-HB-PRP∼T vaccine versus separate DTwP-HB-PRP∼T and IPV vaccines at 12–24 months of age and safety and immunogenicity of a booster dose of DTwP-IPV-HB-PRP∼T in healthy infants in India
por: Mangarule, S, et al.
Publicado: (2022) -
Immunogenicity and Safety of a Hexavalent DTwP-IPV-HB-PRP~T Vaccine Versus Separate DTwP-HB-PRP~T, bOPV, and IPV Vaccines Administered at 2, 4, 6 Months of Age Concomitantly With Rotavirus and Pneumococcal Conjugate Vaccines in Healthy Infants in Thailand
por: Sanchez, Leilani, et al.
Publicado: (2023) -
Lot-to-lot consistency of a hexavalent DTwP-IPV-HB-PRP∼T vaccine and non-inferiority to separate DTwP-HB-PRP∼T and IPV antigen-matching vaccines at 6–8, 10–12, and 14–16 weeks of age co-administered with oral rotavirus vaccine in healthy infants in India: A multi-center, randomized, controlled study
por: Mangarule, S, et al.
Publicado: (2022) -
Immunological Links to Nonspecific Effects of DTwP and BCG Vaccines on Infant Mortality
por: Claesson, Mogens Helweg
Publicado: (2011) -
A phase I, open label, clinical study to assess the safety and immunogenicity of indigenously developed liquid (DTwP-HepB-IPV-Hib) hexavalent combination vaccine in healthy toddlers aged 16–24 months
por: Sharma, Hitt, et al.
Publicado: (2022)